FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesEuropean Roadmap to Lift COVID-19 Containment
Topics: Health Care, Strategic Planning
White Paper
Free
EAP video blog
Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning
Video
Members
Examining Technology-Driven Trends in the Clinical Supply Chain
Topics: Pharma Industry, Technology
Position Paper
Free
